Animal models for chronic lymphocytic leukemia

Journal of Cellular Biochemistry

Volumn 100, Issue 5, 2007, Pages 1109-1118

  Pekarsky, Yuri ^a,b   Zanesi, Nicola ^a   Aqeilan, Rami I ^a   Croce, Carlo M ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

B cell; Mouse model; Tcl1

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ONCOPROTEIN; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN TCL1; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; DISEASE COURSE; GENE OVEREXPRESSION; GENOTYPE PHENOTYPE CORRELATION; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TCL1 GENE; TRANSGENIC MOUSE;

ANIMALS; DISEASE MODELS, ANIMAL; LEUKEMIA, LYMPHOCYTIC, CHRONIC;

ANIMALIA; MUS; MUS MUSCULUS;

EID: 33947608617     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21147     Document Type: Article

References (49)

1. Ahmed NN, Franke TF, Bellacosa A, Datta K, Gonzalez-Portal ME, Taguchi T, Testa JR, Tsichlis PN. 1993. The proteins encoded by c-akt and v-akt differ in post-translational modification, subcellular localization and oncogenic potential. Oncogene 8:1957-1963.
2. Bichi R, Shinton SA, Martin ES, Koval A, Calin GA, Cesari R, Russo G, Hardy RR, Croce CM. 2002. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci USA 99:6955-6960.
3. Bullrich F, Croce C. 2001. Molecular biology of chronic lymphocytic leukemia. Cheson Bruce, editor. Chronic lymphocytic leukemias, 2nd edn. Revised and expanded, New York: Marcel Dekker, Inc. pp 9-32.
4. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, Rassenti L, Kipps T, Negrini M, Bullrich F, Croce CM. 2002. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99:15524-15529.
5. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, Iuliano R, Palumbo T, Pichiorri F, Roldo C, Garzon R, Sevignani C, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M, Croce CM. 2005. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 353:1793-1801.
6. Calnan BJ, Szychowski S, Chan FK, Cado D, Winoto A. 1995. A role for the orphan steroid receptor Nur77 in apoptosis accompanying antigen-induced negative selection. Immunity 3:273-282.
7. Chan TO, Rittenhouse SE, Tsichlis PN. 1999. AKT/PKB and other D3 phosphoinositide-regulated kinases: Kinase activation by phosphoinositide- dependent phosphorylation. Annu Rev Biochem 68:965-1014.
8. Chiorazzi N, Ferrarini M. 2003. B cell chronic lymphocytic leukemia: Lessons learned from studies of the B cell antigen receptor. Annu Rev Immunol 21:841-894.
9. Chiorazzi N, Rai KR, Ferrarini M. 2005. Chronic lymphocytic leukemia. N Engl J Med 352:804-815.
10. Chung JY, Park YC, Ye H, Wu H. 2002. All TRAFs are not created equal: Common and distinct molecular mechanisms of TRAF-mediated signal transduction. J Cell Sci 115:679-688.
11. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M, Croce CM. 2005. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 102:13944-13949.
12. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. 1995. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378:785-789.
13. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, Buchbinder A, Budman D, Dittmar K, Kolitz J, Lichtman SM, Schulman P, Vinciguerra VP, Rai KR, Ferrarini M, Chiorazzi N. 1999. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94:1840-1847.
14. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, Dohner K, Bentz M, Lichter P. 2000. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910-1916.
15. Du K, Montminy M. 1998. CREB is a regulatory target for the protein kinase Akt/PKB. J Biol Chem 273:32377-32379.
16. Fais F, Ghiotto F, Hashimoto S, Sellars B, Valette A, Allen SL, Schulman P, Vinciguerra VP, Rai K, Rassenti LZ, Kipps TJ, Dighiero G, Schroeder HW, Jr., Ferrarini M, Chiorazzi N. 1998. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 102:1515-1525.
17. Frith CH, Highman B, Burger G, Sheldon WD. 1983. Spontaneous lesions in virgin and retired breeder BALB/ c and C57BL/6 mice. Lab Anim Sci 33:273-286.
18. Ghiotto F, Fais F, Valetto A, Albesiano E, Hashimoto S, Dono M, Ikematsu H, Allen SL, Kolitz J, Rai KR, Nardini M, Tramontano A, Ferrarini M, Chiorazzi N. 2004. Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia. J Clin Invest 113:1008-1016.
19. Haiat S, Billard C, Quiney C, Ajchenbaum-Cymbalista F, Kolb JP. 2006. Role of BAFF and APRIL in human B-cell chronic lymphocytic leukaemia. Immunology 118:281-292.
20. Hazel TG, Nathans D, Lau LF. 1988. A gene inducible by serum growth factors encodes a member of the steroid and thyroid hormone receptor super-family. Proc Natl Acad Sci USA 85:8444-8448.
21. Herling M, Patel KA, Khalili J, Schlette E, Kobayashi R, Medeiros LJ, Jones D. 2006. TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state. Leukemia 20:280-285.
22. Hoyer KK, French SW, Turner DE, Nguyen MT, Renard M, Malone CS, Knoetig S, Qi CF, Su TT, Cheroutre H, Wall R, Rawlings DJ, Morse HC, 3rd, Teitell MA. 2002. Dysregulated TCL1 promotes multiple classes of mature B cell lymphoma. Proc Natl Acad Sci USA 99:14392-14397.
23. Johnson TA, Rassenti LZ, Kipps TJ. 1997. Ig VH1 genes expressed in B cell chronic lymphocytic leukemia exhibit distinctive molecular features. J Immunol 158:235-246.
24. Johnson AJ, Lucas DM, Muthusamy N, Smith LL, Edwards RB, De Lay MD, Croce CM, Grever MR, Byrd JC. 2006. Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia. Blood 108:1334-1338.
25. Kantor AB, Herzenberg LA. 1993. Origin of murine B cell lineages. Annu Rev Immunol 11:501-538.
26. Katsumata M, Siegel RM, Louie DC, Miyashita T, Tsujimoto Y, Nowell PC, Greene MI, Reed JC. 1992. Differential effects of Bcl-2 on T and B cells in transgenic mice. Proc Natl Acad Sci USA 89:11376-11380.
27. Kunstle G, Laine J, Pierron G, Kagami Si S, Nakajima H, Hoh F, Roumestand C, Stern MH, Noguchi M. 2002. Identification of Akt association and oligomerization domains of the Akt kinase coactivator TCL1. Mol Cell Biol 22:1513-1525.
28. Kyasa MJ, Hazlett L, Parrish RS, Schichman SA, Zent CS. 2004. Veterans with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have a markedly increased rate of second malignancy, which is the most common cause of death. Leuk Lymphoma 45:507-513.
29. Laine J, Kunstle G, Obata T, Sha M, Noguchi M. 2000. The protooncogene TCL1 is an Akt kinase coactivator. Mol Cell 6:395-407.
30. Lee SY, Reichlin A, Santana A, Sokol KA, Nussenzweig MC, Choi Y. 1997. TRAF2 is essential for JNK but not NF-kappaB activation and regulates lymphocyte proliferation and survival. Immunity 7:703-713.
31. Liu ZG, Smith SW, McLaughlin KA, Schwartz LM, Osborne BA. 1994. Apoptotic signals delivered through the T-cell receptor of a T-cell hybrid require the immediate-early gene nur77. Nature 367:281-284.
32. Masuyama N, Oishi K, Mori Y, Ueno T, Takahama Y, Gotoh Y. 2001. Akt inhibits the orphan nuclear receptor Nur77 and T-cell apoptosis. J Biol Chem 276:32799-32805.
33. Mok CL, Gil-Gomez G, Williams O, Coles M, Taga S, Tolaini M, Norton T, Kioussis D, Brady HJ. 1999. Bad can act as a key regulator of T cell apoptosis and T cell development. J Exp Med 189:575-586.
34. Narducci MG, Pescarmona E, Lazzeri C, Signoretti S, Lavinia AM, Remotti D, Scala E, Baroni CD, Stoppacciaro A, Croce CM, Russo G. 2000. Regulation of TCL1 expression in B- and T-cell lymphomas and reactive lymphoid tissues. Cancer Res 60:2095-2100.
35. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. 1999. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401:82-85.
36. Palamarchuk A, Efanov A, Maximov V, Aqeilan RI, Croce CM, Pekarsky Y. 2005a. Akt phosphorylates and regulates Pdcd4 tumor suppressor protein. Cancer Res 65: 11282-11286.
37. Palamarchuk A, Efanov A, Maximov V, Aqeilan RI, Croce CM, Pekarsky Y. 2005b. Akt phosphorylates Tal1 oncoprotein and inhibits its repressor activity. Cancer Res 65:4515-4519.
38. Parekh K, Rusch V, Kris M. 1999. The clinical course of lung carcinoma in patients with chronic lymphocytic leukemia. Cancer 86:1720-1723.
39. Pekarsky Y, Koval A, Hallas C, Bichi R, Tresini M, Malstrom S, Russo G, Tsichlis P, Croce CM. 2000. Tcl1 enhances Akt kinase activity and mediates its nuclear translocation. Proc Natl Acad Sci USA 97:3028-3033.
40. Pekarsky Y, Hallas C, Palamarchuk A, Koval A, Bullrich F, Hirata Y, Bichi R, Letofsky J, Croce CM. 2001. Akt phosphorylates and regulates the orphan nuclear receptor Nur77. Proc Natl Acad Sci USA 98:3690-3694.
41. Pekarsky Y, Calin GA, Aqeilan R. 2005. Chronic lymphocytic leukemia: Molecular genetics and animal models. Curr Top Microbiol Immunol 294:51-70.
42. Flanelles L, Carvalho-Pinto CE, Hardenberg G, Smaniotto S, Savino W, Gomez-Caro R, Alvarez-Mon M, de Jong J, Eldering E, Martinez AC, Medema JP, Hahne M. 2004. APRIL promotes B-1 cell-associated neoplasm. Cancer Cell 6:399-408.
43. Robak T. 2004. Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukemia. Hematology 9:387-400.
44. Said JW, Hoyer KK, French SW, Rosenfelt L, Garcia-Lloret M, Koh PJ, Cheng TC, Sulur GG, Pinkus GS, Kuehl WM, Rawlings DJ, Wall R, Teitell MA. 2001. TCL1 oncogene expression in B cell subsets from lymphoid hyperplasia and distinct classes of B cell lymphoma. Lab Invest 81:555-564.
45. Sgambati M, Linet M, Devesa S. 2001. Chronic lymphocytic leukemia, epidemiological, familial, and genetic aspects. In: Cheson Bruce, editor. Chronic lymphocytic leukemias, 2nd edn. Revised and expanded, New York: Marcel Dekker, Inc. pp 33-62.
46. Virgilio L, Narducci MG, Isobe M, Billips LG, Cooper MD, Croce CM, Russo G. 1994. Identification of the TCL1 gene involved in T-cell malignancies. Proc Natl Acad Sci USA 91:12530-12534.
47. Yan XJ, Albesiano E, Zanesi N, Yancopoulos S, Sawyer A, Romano E, Petlickovski A, Efremov DG, Croce CM, Chiorazzi N. 2006. B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia. Proc Natl Acad Sci USA 103:11713-11718.
48. Zanesi N, Aqeilan R, Drusco A, Kaou M, Sevignani C, Costinean S, Bortesi L, La Rocca G, Koldovsky P, Volinia S, Mancini R, Calin G, Scott CP, Pekarsky Y, Croce CM. 2006. Effect of rapamycin on mouse chronic lymphocytic leukemia and the development of nonhematopoietic malignancies in E{micro}-TCL1 transgenic mice. Cancer Res 66:915-920.
49. Zapata JM, Krajewska M, Morse HC, 3rd, Choi Y, Reed JC. 2004. TNF receptor-associated factor. TRAF) domain and Bcl-2 cooperate to induce small B cell lymphoma/chronic lymphocytic leukemia in transgenic mice. Proc Natl Acad Sci USA 101:16600-16605.